GEMIN4 functions as a coregulator of the mineralocorticoid receptor
The mineralocorticoid receptor (MR) is a member of the nuclear receptor superfamily. Pathological activation of the MR causes cardiac fibrosis and heart failure, but clinical use of MR antagonists is limited by the renal side effect of hyperkalemia. Coregulator proteins are known to be critical for nuclear receptor-mediated gene expression. Identification of coregulators, which mediate MR activity in a tissue-specific manner, may allow for the development of novel tissue-selective MR modulators that confer cardiac protection without adverse renal effects. Our earlier studies identified a consensus motif among MR-interacting peptides, MPxLxxLL. Gem (nuclear organelle)-associated protein 4 (GEMIN4) is one of the proteins that contain this motif. Transient transfection experiments in HEK293 and H9c2 cells demonstrated that GEMIN4 repressed agonist-induced MR transactivation in a cell-specific manner. Furthermore, overexpression of GEMIN4 significantly decreased, while knockdown of GEMIN4 increased, the mRNA expression of specific endogenous MR target genes. A physical interaction between GEMIN4 and MR is suggested by their nuclear co-localization upon agonist treatment. These findings indicate that GEMIN4 functions as a novel coregulator of the MR..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2015 |
|---|---|
| Erschienen: |
2015 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:54 |
|---|---|
| Enthalten in: |
Journal of molecular endocrinology - 54(2015), 2, Seite 149-160 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yang, Jun [VerfasserIn] |
|---|
| Links: |
|---|
| doi: |
10.1530/JME-14-0078 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC1958659797 |
|---|
| LEADER | 01000caa a2200265 4500 | ||
|---|---|---|---|
| 001 | OLC1958659797 | ||
| 003 | DE-627 | ||
| 005 | 20230514104338.0 | ||
| 007 | tu | ||
| 008 | 160206s2015 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1530/JME-14-0078 |2 doi | |
| 028 | 5 | 2 | |a PQ20160617 |
| 035 | |a (DE-627)OLC1958659797 | ||
| 035 | |a (DE-599)GBVOLC1958659797 | ||
| 035 | |a (PRQ)c1191-99bcbe09624a9fc2de42e5e9a60152f133b58eb4e458872e8010ca3e6f384e9e0 | ||
| 035 | |a (KEY)0191317420150000054000200149gemin4functionsasacoregulatorofthemineralocorticoi | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |a 540 |q DNB |
| 084 | |a 44.89 |2 bkl | ||
| 100 | 1 | |a Yang, Jun |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a GEMIN4 functions as a coregulator of the mineralocorticoid receptor |
| 264 | 1 | |c 2015 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 520 | |a The mineralocorticoid receptor (MR) is a member of the nuclear receptor superfamily. Pathological activation of the MR causes cardiac fibrosis and heart failure, but clinical use of MR antagonists is limited by the renal side effect of hyperkalemia. Coregulator proteins are known to be critical for nuclear receptor-mediated gene expression. Identification of coregulators, which mediate MR activity in a tissue-specific manner, may allow for the development of novel tissue-selective MR modulators that confer cardiac protection without adverse renal effects. Our earlier studies identified a consensus motif among MR-interacting peptides, MPxLxxLL. Gem (nuclear organelle)-associated protein 4 (GEMIN4) is one of the proteins that contain this motif. Transient transfection experiments in HEK293 and H9c2 cells demonstrated that GEMIN4 repressed agonist-induced MR transactivation in a cell-specific manner. Furthermore, overexpression of GEMIN4 significantly decreased, while knockdown of GEMIN4 increased, the mRNA expression of specific endogenous MR target genes. A physical interaction between GEMIN4 and MR is suggested by their nuclear co-localization upon agonist treatment. These findings indicate that GEMIN4 functions as a novel coregulator of the MR. | ||
| 540 | |a Nutzungsrecht: © 2015 Society for Endocrinology. | ||
| 650 | 4 | |a Cell Nucleus - drug effects | |
| 650 | 4 | |a Ribonucleoproteins, Small Nuclear - metabolism | |
| 650 | 4 | |a Nuclear Proteins - metabolism | |
| 650 | 4 | |a Transcriptional Activation - drug effects | |
| 650 | 4 | |a Protein Transport - drug effects | |
| 650 | 4 | |a Receptors, Mineralocorticoid - metabolism | |
| 650 | 4 | |a Repressor Proteins - metabolism | |
| 650 | 4 | |a Aldosterone - pharmacology | |
| 650 | 4 | |a Ribonucleoproteins, Small Nuclear - chemistry | |
| 650 | 4 | |a Cell Nucleus - metabolism | |
| 700 | 1 | |a Fuller, Peter J |4 oth | |
| 700 | 1 | |a Morgan, James |4 oth | |
| 700 | 1 | |a Shibata, Hirotaka |4 oth | |
| 700 | 1 | |a Clyne, Colin D |4 oth | |
| 700 | 1 | |a Young, Morag J |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of molecular endocrinology |d Bristol : Society for Endocrinology, 1988 |g 54(2015), 2, Seite 149-160 |w (DE-627)130436895 |w (DE-600)645012-X |w (DE-576)018259146 |x 0952-5041 |7 nnns |
| 773 | 1 | 8 | |g volume:54 |g year:2015 |g number:2 |g pages:149-160 |
| 856 | 4 | 1 | |u http://dx.doi.org/10.1530/JME-14-0078 |3 Volltext |
| 856 | 4 | 2 | |u http://www.ncbi.nlm.nih.gov/pubmed/25555524 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a GBV_ILN_2011 | ||
| 912 | |a GBV_ILN_4125 | ||
| 936 | b | k | |a 44.89 |q AVZ |
| 951 | |a AR | ||
| 952 | |d 54 |j 2015 |e 2 |h 149-160 | ||